List of Excipients in Branded Drug EQUALINE NICOTINE

Generic Drugs Containing EQUALINE NICOTINE

Company	Ingredient	NDC	Excipient
Supervalu Inc	nicotine polacrilex	41163-012	ACESULFAME POTASSIUM
Supervalu Inc	nicotine polacrilex	41163-012	CALCIUM CARBONATE
Supervalu Inc	nicotine polacrilex	41163-012	CARNAUBA WAX
Supervalu Inc	nicotine polacrilex	41163-012	GELATIN
Supervalu Inc	nicotine polacrilex	41163-012	MANNITOL
Supervalu Inc	nicotine polacrilex	41163-012	MENTHOL
Supervalu Inc	nicotine polacrilex	41163-012	POLACRILIN

What are the Most Frequently-Used Excipients in EQUALINE NICOTINE?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	ASPARTAME
2	CALCIUM CARBONATE
2	CARNAUBA WAX
1	D&C YELLOW NO. 10
2	GELATIN
2	MAGNESIUM STEARATE

Equaline Nicotine Excipient Strategy and Commercial Opportunity Analysis

Last updated: August 3, 2026

Equaline Nicotine is an over-the-counter nicotine replacement product, generally marketed as nicotine polacrilex chewing gum in 2 mg and 4 mg strengths. Its commercial position depends less on active-ingredient exclusivity than on excipient performance, flavor acceptance, chew texture, dose-release behavior, packaging, regulatory compliance, and retail economics. The product is exposed to substantial generic competition, but differentiated excipient systems can support premium private-label positioning, improved adherence, and adjacent nicotine-replacement products.

What is Equaline Nicotine and how is it regulated?

Equaline Nicotine is understood to be a store-brand nicotine polacrilex gum product. Nicotine polacrilex is a nicotine-resin complex that releases nicotine during chewing. The gum is designed for the "chew and park" method, in which the user chews until a tingling sensation develops and then parks the gum between the cheek and gum.

Product attribute	Equaline Nicotine gum
Active ingredient	Nicotine polacrilex
Common strengths	2 mg and 4 mg
Dosage form	Medicated chewing gum
Therapeutic category	Smoking cessation, nicotine replacement therapy
Regulatory pathway	OTC nicotine replacement framework
Primary users	Adults attempting to stop or reduce smoking
Key commercial variables	Taste, mouthfeel, nicotine release, packaging, price
Biosimilar relevance	None

FDA nicotine-replacement products are subject to specific labeling, dosing, warning, and packaging requirements. The FDA’s OTC nicotine-replacement framework covers nicotine gum, lozenges, and transdermal systems, while product labeling must comply with applicable Drug Facts requirements.[1,2]

Equaline’s exact legal manufacturer and formulation may vary by market, package size, flavor, and private-label supply arrangement. The relevant commercial analysis is therefore the nicotine polacrilex gum platform rather than a single universal Equaline formulation.

What excipients are used in Equaline Nicotine gum?

Typical nicotine polacrilex gum formulations use a gum base, sweeteners, buffering agents, humectants, lubricants, and flavors. Publicly marketed nicotine gum products commonly identify ingredients such as sorbitol, sodium carbonate, glycerin, gum base, talc, and flavoring agents. Exact excipient identity and concentration depend on the supplier and flavor.[3]

Core excipient functions

Excipient category	Typical function	Commercial impact
Gum base	Provides chewable matrix and controls residence time	Determines texture, consumer acceptance, and release profile
Sorbitol	Bulk sweetener and bodying agent	Supports sugar-free claims and reduces cariogenicity
Sodium carbonate	Buffering agent	Raises local pH and promotes nicotine release and absorption
Glycerin	Humectant and plasticizer	Controls flexibility, moisture, and chew softness
Talc or mineral processing aid	Anti-stick and processing aid	Supports manufacturing and tablet or gum handling
Flavor system	Masks nicotine bitterness and harshness	Drives repeat purchase and adherence
High-intensity sweeteners	Sweetness enhancement	Reduces sugar content while improving taste
Antioxidants or stabilizers	Protect flavor and product quality	Helps manage shelf life and packaging requirements

The most important excipient is the gum base. Unlike a conventional tablet, medicated chewing gum is both a delivery system and a consumer product. The base must provide sufficient mechanical resilience for several minutes of chewing while allowing nicotine to migrate into saliva at a controlled rate.

How does the excipient system control nicotine release?

Nicotine release is governed by the interaction between the nicotine-resin complex, saliva, buffering agents, chewing force, and gum-base composition. The formulation must release enough nicotine to reduce withdrawal symptoms without producing excessive bitterness, throat irritation, nausea, or mouth discomfort.

Buffering strategy

Sodium carbonate or comparable alkaline buffers are central to nicotine-gum performance. Increasing local pH favors conversion of nicotine toward the free-base form, which can improve absorption through the buccal mucosa. The buffer level must remain within a narrow performance range:

• Too little buffer can reduce nicotine release and weaken pharmacological effect.
• Too much buffer can increase irritation, alkalinity, chalkiness, and unpleasant mouthfeel.
• Uneven buffer distribution can create dose variability during chewing.

A differentiated formulation opportunity exists in controlling buffer particle size, dispersion, and release rather than simply increasing buffer concentration.

Gum-base strategy

The gum base affects:

• Initial hardness
• Chew resistance
• Rate of nicotine liberation
• Residual flavor
• Stickiness
• Mouth-coating behavior
• Product stability under heat

A softer base may improve use by older consumers or patients with dental limitations, but it can increase stickiness and accelerate release. A firmer base may provide longer release but reduce adherence if chewing is uncomfortable.

Sweetener and flavor strategy

Nicotine has a bitter, peppery taste. Flavor failure is a major practical risk because users may discontinue therapy despite adequate nicotine delivery. Commercially relevant flavor systems include mint, fruit, cinnamon, and menthol-type profiles. A flavor system should be evaluated across the full chewing period rather than only at initial placement.

High-intensity sweeteners can reduce caloric content, but some combinations create delayed bitterness or cooling effects that conflict with nicotine’s sensory profile. Sorbitol can improve bulk and sweetness but may cause gastrointestinal discomfort at high cumulative consumption.

What formulations are protected by patents?

The active ingredient, nicotine, is not commercially protected by a current composition-of-matter patent for nicotine gum. Early nicotine-gum inventions and foundational delivery concepts are generally old and would not provide a practical barrier to modern private-label entry.

Potentially relevant intellectual-property categories include:

1. Nicotine-resin complexes and ion-exchange systems.
2. Gum-base compositions that control release.
3. Multi-phase or layered chewing-gum structures.
4. Flavor-masking systems.
5. Buffer-release systems.
6. Manufacturing processes for medicated gum.
7. Child-resistant containers and unit-dose packaging.
8. Combination nicotine products.
9. Digital adherence systems linked to packaging.

A supplier seeking defensible differentiation would likely pursue narrow formulation or process claims rather than broad claims covering nicotine gum generally. Patent strength would depend on comparative dissolution data, sensory data, stability results, and evidence that the claimed excipient combination produces an unexpected performance advantage.

When does Equaline Nicotine lose exclusivity?

Equaline Nicotine does not have a conventional prescription-drug exclusivity timeline. OTC nicotine gum is competing in a mature category with multiple branded and private-label products.

Exclusivity issue	Equaline Nicotine assessment
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No product-specific basis established
Orange Book exclusivity	Not generally applicable to monograph-based private-label gum
Core nicotine patent	Expired or commercially non-blocking
Formulation patent risk	Possible but claim-specific
Generic competition	High
Private-label competition	High

The relevant market-entry question is not the expiration of an Equaline patent. It is whether a competing manufacturer can satisfy the applicable FDA requirements, establish product quality, secure supply, and obtain retail distribution at a lower or comparable cost.

What is the Orange Book status of Equaline Nicotine?

Equaline Nicotine is not generally expected to have an Orange Book listing comparable to an innovator prescription product. Orange Book protection is primarily relevant to approved prescription and certain nonprescription drug applications. A store-brand nicotine-gum product marketed under the OTC framework does not normally create an Orange Book patent-blocking strategy.

That limits the value of Paragraph IV litigation against Equaline itself. Competitors would more likely enter through their own OTC-compliant nicotine polacrilex product rather than challenge an Equaline patent estate.

Are there Paragraph IV challenges against Equaline Nicotine?

No commercially material Paragraph IV challenge against Equaline Nicotine is established in the public record used for this analysis. The reason is structural: an OTC private-label nicotine gum product generally does not present the same listed-drug patent certification profile as a prescription NDA product.

Paragraph IV litigation may still arise around a branded nicotine-gum NDA, a reformulated product, a proprietary delivery system, or a newly patented combination product. That litigation would affect the broader nicotine-replacement market rather than necessarily blocking Equaline.

What FDA regulatory requirements affect excipient selection?

Excipient changes must be evaluated against product quality, labeling, safety, and manufacturing requirements. Key controls include:

• Identity and purity of each excipient
• Food, drug, or compendial status where applicable
• Residual solvents and elemental impurities
• Microbial quality
• Heavy-metal controls
• Allergen and sensitivity assessment
• Stability under heat and humidity
• Uniformity of nicotine content
• In-vitro release performance
• Leachables and extractables from packaging
• Flavor-system compliance
• Child-resistant packaging requirements

For nicotine gum, an excipient change can alter nicotine release even when the active ingredient and nominal strength remain unchanged. A reformulation therefore requires comparative analytical testing and may require regulatory review depending on the product’s legal pathway and the extent of the change.

What commercial opportunities exist in Equaline Nicotine excipients?

1. Improved taste and adherence

The strongest commercial opportunity is reducing bitterness and mouth irritation. A supplier could develop a proprietary flavor-and-sweetener system that maintains acceptable taste for the full recommended chewing period.

Potential value metrics include:

• Lower early discontinuation
• Higher repeat purchase
• Better completion of cessation programs
• Lower consumer complaints
• Greater acceptance of the 4 mg strength

2. Softer gum for broader use

A softer, less adhesive gum could address consumers with dentures, dental sensitivity, or low chewing tolerance. The formulation must preserve mechanical integrity and avoid excessive gum-base adhesion to dental appliances.

3. Faster or more predictable nicotine release

A controlled-release excipient system could improve consistency between users with different chewing styles. Useful technologies may include:

• Fine-particle buffer dispersion
• Modified nicotine-resin particle size
• Layered gum structures
• Hydrophilic release modifiers
• Optimized gum-base polarity

The commercial claim must be supported by comparative release and pharmacokinetic data.

4. Sustainable excipient and packaging systems

Plastic reduction is more commercially actionable in packaging than in the gum itself. Opportunities include recyclable blister materials, lower-plastic cartons, and high-barrier films that preserve nicotine and flavor stability.

5. Adjacent dosage forms

An Equaline platform could expand into:

• Nicotine lozenges
• Mini-lozenges
• Nicotine pouches
• Chewable tablets
• Oral films
• Combination gum-and-lozenge cessation packs

Each dosage form would require separate formulation, quality, and regulatory evaluation. The excipient opportunity is strongest where existing nicotine products have taste, irritation, or convenience limitations.

How strong is the patent estate for Equaline Nicotine?

The patent estate is likely weak at the core-product level and potentially moderate for narrowly defined improvements.

IP layer	Estimated protection potential
Nicotine active ingredient	Very low
Standard nicotine polacrilex gum	Low
Conventional sorbitol-buffer-gum formulation	Low
Novel flavor masking	Moderate
Release-controlled gum base	Moderate
Manufacturing process	Moderate
Proprietary packaging	Low to moderate
Digital adherence system	Moderate
New combination product	Moderate to high, depending on claims

Trade secrets may be more valuable than patents for excipient ratios, mixing order, gum-base processing, flavor premixes, and supplier specifications. A patent application should focus on reproducible technical differences with measurable benefits.

Which companies are challenging Equaline Nicotine commercially?

Equaline competes with private-label and branded nicotine-replacement products, including Nicorette and retailer brands such as Equate, CVS Health, Walgreens, Rite Aid, and GoodSense, depending on market availability. Competition is based on price, flavor, package count, retail placement, and perceived efficacy.

The market has low switching costs. A consumer can move between equivalent nicotine strengths without changing the cessation method. This makes flavor, texture, package convenience, and price more important than brand loyalty.

What generic entry risks exist for Equaline Nicotine?

Generic and private-label entry risk is high because:

• Nicotine is widely available.
• The dosage form is established.
• Regulatory expectations are familiar.
• The product has no apparent molecule-level exclusivity.
• Retailers can source from multiple contract manufacturers.
• Consumers are accustomed to store-brand nicotine gum.

The main barriers are manufacturing capability, acceptable sensory performance, stability, quality systems, and retail qualification. These are meaningful operational barriers but weak legal barriers.

What licensing deals could support Equaline Nicotine?

The most commercially relevant licensing opportunities would involve:

1. A proprietary gum base with improved chew characteristics.
2. A taste-masking system supported by sensory testing.
3. A nicotine-release technology with comparative data.
4. A contract manufacturing platform for multiple nicotine strengths.
5. Sustainable high-barrier packaging.
6. A cessation adherence platform linked to retail products.

A licensing agreement should distinguish rights to the excipient technology, finished-product manufacturing, territory, flavor variants, and future dosage forms. Royalty value would depend on demonstrated consumer adherence or manufacturing savings rather than broad ownership of nicotine gum.

What revenue exposure does Equaline Nicotine create?

Equaline-specific revenue is not generally disclosed separately by retailers or suppliers. The product is likely a low-priced, high-volume OTC item with limited per-unit margin. Its economic value is driven by:

• Retailer shelf access
• Package size
• Repeat purchase
• Contract manufacturing cost
• Flavor-specific demand
• Seasonal cessation demand
• Cross-selling with patches and lozenges

Excipient suppliers should target cost-neutral or cost-saving improvements unless the formulation creates measurable adherence or premium-price benefits. A minor increase in excipient cost is difficult to pass through in a private-label product without evidence of higher velocity or lower returns.

Key Takeaways

• Equaline Nicotine is best analyzed as an OTC nicotine polacrilex gum platform.
• The core product has high generic and private-label exposure.
• Excipient value lies in taste, gum texture, nicotine-release consistency, stability, and packaging.
• Sodium carbonate, gum base, sorbitol, glycerin, flavors, and sweeteners are central performance variables.
• Orange Book and Paragraph IV strategies are generally weak for a private-label OTC nicotine gum.
• The strongest potential IP positions involve flavor masking, controlled release, manufacturing processes, or packaging.
• Commercial success depends on adherence and retail economics more than active-ingredient exclusivity.
• Biosimilar risk does not apply because nicotine is a small-molecule OTC drug, not a biologic.

FAQs About Equaline Nicotine Excipient Strategy

Can Equaline Nicotine gum be reformulated without changing its strength?

Yes, but excipient changes can alter nicotine release, taste, texture, stability, and labeling compliance. The product must continue to meet applicable quality and regulatory requirements.

Which excipient has the greatest effect on nicotine absorption?

The buffering system, particularly the alkaline buffer level and distribution, has a major effect on nicotine liberation and buccal absorption. Gum-base composition also materially affects release.

Is sorbitol in nicotine gum commercially advantageous?

Yes. Sorbitol provides bulk and sweetness while supporting sugar-free positioning. Its level must be managed because high consumption can cause gastrointestinal effects.

Can a new flavor system support patent protection?

Potentially. Patent strength would require a defined composition and evidence that the system produces an unexpected improvement in bitterness, irritation, stability, or adherence.

Could Equaline expand into nicotine pouches or lozenges?

Yes. The brand platform could extend to other nicotine-replacement formats, but each dosage form would require separate formulation development, quality assessment, regulatory review, and competitive positioning.

References

1. U.S. Food and Drug Administration. (2020). Nicotine replacement therapy drug products for over-the-counter human use. FDA OTC Monograph M012.
2. U.S. Food and Drug Administration. (2023). Drug Facts labeling for nonprescription human drug products. 21 C.F.R. § 201.66.
3. National Library of Medicine. (n.d.). DailyMed: Nicotine polacrilex chewing gum labeling. U.S. National Library of Medicine.
4. U.S. Food and Drug Administration. (2022). OTC monograph drug products: Regulatory framework under the CARES Act. FDA.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.